AbbVie has obtained orphan drug designation from the European Medicines Agency (EMA) and the US FDA for its anti-epidermal growth factor receptor monoclonal antibody drug conjugate, ABT-414, as a treatment for glioblastoma multiforme.
Bristol-Myers Squibb and Allied Minds have formed a new jointly owned enterprise, Allied-Bristol Life Sciences, aimed at advancing discoveries of biopharmaceutical innovations at leading US academic research institutions.
The US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) tablets, developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an addition to diet and exercise to improve glycemic control in adults with type II diabetes.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Spain-based Almirall and AstraZeneca have entered into an agreement, involving Almirall transfering the rights to its respiratory franchise to Astrazeneca for an initial consideration of $875m on completion, and up to $1.22bn in development, launch and sales-related milestones.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Gilead Sciences’ marketing authorisation application for Zydelig to treat chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL).